The multiple organisations supporting this initiative, including Oncopole, will contribute a total of $6.5 million to the Montreal Cancer Consortium over the next two years. As the project catalyst, TFRI is providing $2 million.
The MCC researchers will pursue their works toward improving the treatments of cancer patients through precision and personalized medicine.
The MCC comprises many institutions : the Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Goodman Cancer Research Centre (GCRC), Centre de Recherche Hôpital Maisonneuve-Rosemont (CR-HMR), Institute for Research in Immunology and Cancer (IRIC), Jewish General Hospital (JGH), McGill University, the Université de Montréal, Génome Québec Innovation Centre, and the Research Institute of the McGill University Health Centre (RI-MUHC).
More specifically, Oncopole supports the following project:
Inter-institutional coordination and integration of clinical data and biospecimens from patients treated by the Montreal Cancer Consortium.
This project is set to create and integrate harmonized tissue biobanking through out the various MCC institutions. In this pilot project, a priority will be given to cancers which benefit significantly from immunotherapy as a therapeutic approach while also insuring that biobanks meet registration and certifications criteria. Tissues collected must also help meet the needs of other MCC projects.
This project will also enable to expand, to all MCC members, the use of ATiM, a Biobank Information Management System (BIMS) from the Canadian Tissue Repository Network (http://www.ctrnet.ca/resources/atim).
For this project, the consortium will count on the proven expertise of the following partners: the Cancer Research Network (RRCancer), the Canadian Tissue Repository Network (CTRNet) et Exactis Innovation (Exactis).